Amylin’s Symlin resubmitted
Executive Summary
Amylin submits amended NDA for diabetes agent Symlin June 17, making FDA user fee goal date Dec. 17. Amendment includes dose titration study data requested in October 2001 "approvable letter." Amylin already is planning "concentrated" detailing strategy (1"The Pink Sheet" June 16, 2003, p. 34)...